Schering-Plough Reports Financial Results for 2009 Seco...(1048 Income tax benefit ...)

Date:7/21/2009

1,048 Income tax benefit 27 73 59 187 -- -- -- --- Total purchase accounting adjustments $108 $284 $205 $861 ==== ==== ==== ==== Special, merger and acquisition-related items: --------------------------- Accelerated depreciation (a) $5 $- $7 $- Special, merger and acquisition-related activities (d)/(e) 29 94 106 117 -- -- --- --- Total special, merger and acquisition-related items, pre-tax 34 94 113 117 Income tax benefit 6 7 13 9 - - -- - Total special, merger and acquisition-related items $28 $87 $100 $108 === === ==== ==== Other specified items: ---------------------- Income from respiratory JV termination (f) $- $(64) $- $(64) (Gain) on sale of manufacturing plant (c) - - - (17) Total other specified items, pre-tax - - - (81) Income tax expense - - - (5) - - - --- Total other specified items $- $(64) $- $(76) == ==== == ==== Total purchase accounting adjustments, special,
'/>"/>

SOURCE Schering-Plough Corporation Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27
Related biology technology :

1. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
2. Schering-Plough Announces Pricing of Senior Notes Offering
3. Schering-Plough to Webcast Presentation at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
4. Schering-Plough Receives Approval from European Commission for Planned Acquisition of Organon BioSciences N.V.
5. Schering-Plough Completes Acquisition of Organon BioSciences
6. Schering-Plough Wins Three of Scrips Top Pharma Industry Awards
7. Schering-Plough Schedules Conference Call and Webcast for 2007 Fourth Quarter, Full-Year Financial Result
8. Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference
9. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
10. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
11. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma